Holen Sie sich die Stockscreener-App
34.60
1.62%
-0.57
Handel nachbörslich:
35.50
0.90
+2.60%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$35.17
Offen:
$34.99
24-Stunden-Volumen:
1.27M
Relative Volume:
0.82
Marktkapitalisierung:
$3.33B
Einnahmen:
$610.16M
Nettoeinkommen (Verlust:
$-532.93M
KGV:
-6.2583
EPS:
-5.5287
Netto-Cashflow:
$-442.30M
1W Leistung:
+3.19%
1M Leistung:
+15.03%
6M Leistung:
-11.24%
1J Leistung:
-32.14%
1-Tages-Spanne:
$34.35
$35.38
1-Wochen-Bereich:
$33.94
$35.95
52-Wochen-Spanne:
$25.81
$53.47
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
34.60 | 3.39B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Why Ultragenyx Pharmaceutical Inc. stock appeals to dividend seekersWeekly Profit Analysis & Reliable Breakout Stock Forecasts - newser.com
Is Ultragenyx Pharmaceutical Inc. stock attractive after correctionWatch List & Long Hold Capital Preservation Plans - newser.com
Is Ultragenyx Pharmaceutical Inc. still worth holding after the dip2025 Retail Activity & Stock Market Timing Techniques - newser.com
Y Intercept Hong Kong Ltd Grows Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Is Ultragenyx Pharmaceutical Inc. stock dividend yield sustainablePortfolio Performance Report & Long-Term Investment Growth Plans - newser.com
Is Ultragenyx Pharmaceutical Inc. stock a top momentum playWeekly Loss Report & Free Long-Term Investment Growth Plans - newser.com
Will Ultragenyx Pharmaceutical Inc. see short term momentum2025 Winners & Losers & Weekly Setup with High ROI Potential - newser.com
Can Ultragenyx Pharmaceutical Inc. (UP0) stock surprise with quarterly resultsCEO Change & Long-Term Capital Growth Strategies - newser.com
Is this a good reentry point in Ultragenyx Pharmaceutical Inc.Bond Market & Safe Capital Growth Tips - newser.com
Will Ultragenyx Pharmaceutical Inc. stock benefit from upcoming earnings reports2025 Fundamental Recap & Risk Controlled Stock Alerts - newser.com
Earnings visualization tools for Ultragenyx Pharmaceutical Inc.Long Setup & Consistent Growth Stock Picks - newser.com
Can Ultragenyx Pharmaceutical Inc. stock sustain revenue growthEarnings Growth Summary & Accurate Entry/Exit Alerts - newser.com
Ultragenyx Pharmaceutical Inc expected to post a loss of $1.23 a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL) - The Globe and Mail
Ultragenyx doses first subject in study of GTX-102 for angelman syndrome - Clinical Trials Arena
What hedge fund moves indicate for Ultragenyx Pharmaceutical Inc. (UP0) stockTreasury Yields & Daily Oversold Stock Bounce Ideas - newser.com
Emerald Mutual Fund Advisers Trust Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Chart based analysis of Ultragenyx Pharmaceutical Inc. trendsJuly 2025 Institutional & Verified Short-Term Plans - newser.com
How risky is Ultragenyx Pharmaceutical Inc. stock now2025 Bull vs Bear & Daily Entry Point Trade Alerts - newser.com
Can Ultragenyx Pharmaceutical Inc. stock weather global recessionJuly 2025 Market Mood & Verified Technical Trade Signals - newser.com
Can Ultragenyx Pharmaceutical Inc. stock deliver sustainable ROE2025 Historical Comparison & Accurate Intraday Trade Tips - newser.com
Can Ultragenyx Pharmaceutical Inc. (UP0) stock hold up in economic slowdownMarket Weekly Review & Safe Capital Growth Trade Ideas - newser.com
Will Ultragenyx Pharmaceutical Inc. stock remain a Wall Street favoriteMarket Performance Summary & Advanced Technical Analysis Signals - newser.com
Ultragenyx Pharmaceutical Inc. (RARE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome - TipRanks
Ultragenyx (RARE) Begins Aurora Study for Angelman Syndrome Trea - GuruFocus
Ultragenyx Pharmaceutical Initiates Aurora Study for Angelman Syndrome - TradingView
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups - The Manila Times
Ultragenyx (NASDAQ: RARE) doses 1st patient in GTX-102 study; ~60 across genotypes - Stock Titan
Emerald Advisers LLC Sells 54,826 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
What analysts say about Ultragenyx Pharmaceutical Inc stockMarket Liquidity Analysis & Small Investment Growth Tips - earlytimes.in
Ultragenyx Pharmaceutical (RARE) to Release Quarterly Earnings on Tuesday - MarketBeat
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know - sharewise.com
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):